BOULDER, Colo., Oct. 25, 2016 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) will report financial results
for the first quarter of fiscal 2017 and hold a conference call to
discuss those results on Tuesday, November
1, 2016. Ron Squarer, Chief Executive Officer, will
lead the call.
Date:
|
Tuesday, November 1,
2016
|
Time:
|
9:00 a.m. Eastern
Time
|
Toll-Free:
|
(844)
464-3927
|
Toll:
|
(765)
507-2598
|
Pass
Code:
|
93600421
|
Webcast, including Replay and Conference Call
Slides:
http://edge.media-server.com/m/p/8qcss7h2
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Five registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162), encorafenib (LGX818) and selumetinib
(AstraZeneca).
CONTACT:
|
Tricia
Haugeto
|
|
Array BioPharma
Inc.
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2017-on-november-1-2016-300350249.html
SOURCE Array BioPharma Inc.